John Parkinson

A 2-dose vaccination regimen did not show protection against mild-to-moderate disease due to the B.1.351 variant.

Melinta Therapeutics’ oritavancin therapy is indicated for treatment of acute bacterial skin and skin structure infections (ABSSSI) in adult patients.

A bamlanivimab study showed a 72% reduction in the incidence of COVID-19 and an 80% reduction of progression in the virus in residents in assisted living facilities and nursing staff.

This Emergency Use Listing (EUL) of this single-shot vaccine opens up the door to much of the developing world to gain access to it.

The investigational candidate has shown to be 55% and 86.3% effective respectively.

While at the earliest stages of potential development, long-acting/extended release (LA/ER) formulations for treatment and prevention of TB could be something to be studied in the future.

Dapivrine (DPV) was studied in 1-month and 3-month durations.

During the pandemic, reduced HIV testing led to concerns about getting people diagnosed and on antiretroviral therapy (ART), and achieving viral suppression (VS).

ViiV Healthcare’s investigational therapy, GSK’254, demonstrated antiviral activity, safety, and tolerability in its phase 2a proof-of-concept findings.

With the highest HIV incidence rate in this part of the country, the need to get people from diagnosis to timely antiretroviral therapy (ART) remains an urgent need.

Merck has developed its investigational islatravir subdermal implant for prevention of HIV infection, and it is going to be studied for a long-term delivery of up to 1 year.

Merck’s islatravir subdermal implant demonstrated it achieved active drug concentrations above the pre-specified pharmacokinetics (pk) threshold at 12 weeks across three doses.

While the world’s focus remains on COVID-19, beyond this ongoing crisis lingers another that requires leadership, innovation, and collaboration from policy makers, the health care community, and the private sector.

Windtree Therapeutics is in a phase 2 clinical trial for its investigational therapy, Lucinactant, which produces a synthetic surfactant being studied for acute lung injury in patients with COVID-19 and acute respiratory distress syndrome (ARDS).

Cue Health's test is over the counter (OTC) and can be utilized at home.

The Luminex test will be able to detect influenza and COVID-19.

Investigators have discovered active substances that can block the replication of coronavirus and may create a pathway for new therapies.

A review of emergency room records showed a very small percentage of patients had acute ischemic strokes, but for those who did, there was an increased risk of requiring long-term care after hospital discharge.

NeuroRx announced results from its phase 2b/3 trial for its investigational therapy, aviptadil, in patients with severe COVID-19.

Investigational therapy, ibrexafungerp, from Scynexis is being studied for fungal infections and is moving closer towards a goal of FDA approval later this year.

The Biden Administration is set to announce the deal officially about a partnership for the biopharmaceutical companies today.

Beginning this week, the agency is funneling air travelers from 2 African countries to a limited amount of US airports.

The variant, B.1.526, was first found in samples dating back to November.

The US Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommendation paves the way for the authorization.

In a phase 3 study, rheumatoid arthritis (RA) therapy, tocilizumab, did not improve clinical status or lower mortality in these patients.

An Israeli study finds it had an 85% effect in lowering disease 2 to 4 weeks after administration of the initial vaccination.

In lab studies, neutralizing antibody activity was reported but there was a reduction shown in both m-RNA vaccines.

This new variant, B.1.525, was discovered in both the United Kingdom and Nigeria, and is now in 11 other countries including the United States.

The World Health Organization (WHO) listed the vaccine for emergency use to enable countries who do not have vaccine agreements in place to work towards vaccinating their populations.

CalciMedica has developed Auxora, a calcium release-activated calcium (CRAC) channel inhibitor, and it has shown it can reduce the levels of D-dimer, a key biomarker associated with COVID-19 mortality.